Romero José Rafael, Sakai Osamu, Rice Mary Berlik, Babikian Viken L
Department of Neurology, Boston University Medical Center, Boston, Massachusetts 02118, USA.
J Neuroimaging. 2007 Jul;17(3):246-50. doi: 10.1111/j.1552-6569.2007.00111.x.
The risk of intracerebral hemorrhage (ICH) in patients receiving antithrombotic therapy is well known. However, there is sparse literature regarding the risk of intracerebral hemorrhage in patients receiving warfarin, who have an intracranial meningioma.
We report a case of a 66-year-old man who developed multifocal ICHs in the context of supratherapeutic anticoagulation. There was sparing of the intracranial meningioma despite the development and growth of multiple intraparenchymal hemorrhages that resulted in death. We also review the literature evaluating the risk of ICH in anticoagulated patients with an intracranial meningioma.
The findings of this case lend further support to the gradually developing notion of relative safety of anticoagulation in patients with meningioma. They also underscore the importance of close monitoring of the INR.
接受抗血栓治疗的患者发生脑出血(ICH)的风险是众所周知的。然而,关于患有颅内脑膜瘤且接受华法林治疗的患者发生脑出血风险的文献却很少。
我们报告了一例66岁男性患者,在抗凝治疗剂量超过治疗范围的情况下发生了多灶性脑出血。尽管发生并出现了多个脑实质内出血并导致患者死亡,但颅内脑膜瘤未出血。我们还回顾了评估抗凝治疗的颅内脑膜瘤患者发生脑出血风险的文献。
该病例的研究结果进一步支持了脑膜瘤患者抗凝治疗相对安全这一逐渐形成的观点。它们还强调了密切监测国际标准化比值(INR)的重要性。